

Cystic Fibrosis (CFTR) Carrier Screening and Diagnostic Testing – Update to Ordering Process

Orderable: Cystic Fibrosis (CFTR) [LAB1233901]

Beginning March 18th, 2025, the Molecular Diagnostics Laboratory will amend the order for Cystic Fibrosis testing to require an indication for testing – “Prenatal Screening” or “Diagnostic.” The “Prenatal Screening” option should be selected when screening for Cystic Fibrosis carrier status during or prior to pregnancy. The “Diagnostic” option should be selected when there is a clinical concern that the patient could have a diagnosis of Cystic Fibrosis. These options will be available in the order screen in EPIC and must be selected to complete the order. This change will not impact the assay results; however, result interpretations specific with the order indication will be reported.

This new order will replace the stand-alone Cystic Fibrosis (CFTR) Carrier Screening and Cystic Fibrosis (CFTR) Diagnosis orderables.

Specimen requirements and turnaround time will remain the same.

Order Prior to March 18 th , 2025	New Order
Cystic Fibrosis (CFTR) Carrier Screening (LAB1230174)	Cystic Fibrosis (CFTR) (LAB1233901)
Cystic Fibrosis (CFTR) Diagnosis (LAB1230175)	

Cystic Fibrosis (CFTR)

✓ Accept

✗ Cancel

Frequency:

Once

At

3/5/2025

Today

Tomorrow

0924

Indication for ordering

Prenatal Screening

Diagnostic

Release to Patient

Immediate

Delay - 3 days

Comments:

+ Add Comments

Specimen Type:

Blood

Specimen Source:

Blood, Arterial

Blood, Capillary

Blood, Central Line

Blood, Venous

Add-on:

No add-on specimen found

CC Results:

+ My List

+ Other

Enter recipients

Next Required

Link Order

✓ Accept

✗ Cancel

For questions, please contact Pathology Client Services at (804) 828-7284 or the Molecular Diagnostics Laboratory at (804) 828-9564.